SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Bergh J) "

Sökning: WFRF:(Bergh J)

Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Iurilli, M. L. C., et al. (författare)
  • Heterogeneous contributions of change in population distribution of body mass index to change in obesity and underweight NCD Risk Factor Collaboration (NCD-RisC)
  • 2021
  • Ingår i: eLife. - : ELIFE SCIENCES PUBLICATIONS LTD. - 2050-084X. ; 10
  • Tidskriftsartikel (refereegranskat)abstract
    • From 1985 to 2016, the prevalence of underweight decreased, and that of obesity and severe obesity increased, in most regions, with significant variation in the magnitude of these changes across regions. We investigated how much change in mean body mass index (BMI) explains changes in the prevalence of underweight, obesity, and severe obesity in different regions using data from 2896 population-based studies with 187 million participants. Changes in the prevalence of underweight and total obesity, and to a lesser extent severe obesity, are largely driven by shifts in the distribution of BMI, with smaller contributions from changes in the shape of the distribution. In East and Southeast Asia and sub-Saharan Africa, the underweight tail of the BMI distribution was left behind as the distribution shifted. There is a need for policies that address all forms of malnutrition by making healthy foods accessible and affordable, while restricting unhealthy foods through fiscal and regulatory restrictions.
  •  
2.
  •  
3.
  •  
4.
  •  
5.
  • Abe, O, et al. (författare)
  • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
  • 2005
  • Ingår i: The Lancet. - : Elsevier. - 1474-547X. ; 365:9472, s. 1687-1717
  • Tidskriftsartikel (refereegranskat)abstract
    • Background Quinquennial overviews (1985-2000) of the randomised trials in early breast cancer have assessed the 5-year and 10-year effects of various systemic adjuvant therapies on breast cancer recurrence and survival. Here, we report the 10-year and 15-year effects. Methods Collaborative meta-analyses were undertaken of 194 unconfounded randomised trials of adjuvant chemotherapy or hormonal therapy that began by 1995. Many trials involved CMF (cyclophosphamide, methotrexate, fluorouracil), anthracycline-based combinations such as FAC (fluorouracil, doxombicin, cyclophosphamide) or FEC (fluorouracil, epirubicin, cyclophosphamide), tamoxifen, or ovarian suppression: none involved taxanes, trastuzumab, raloxifene, or modem aromatase inhibitors. Findings Allocation to about 6 months of anthracycline-based polychemotherapy (eg, with FAC or FEC) reduces the annual breast cancer death rate by about 38% (SE 5) for women younger than 50 years of age when diagnosed and by about 20% (SE 4) for those of age 50-69 years when diagnosed, largely irrespective of the use of tamoxifen and of oestrogen receptor (ER) status, nodal status, or other tumour characteristics. Such regimens are significantly (2p=0 . 0001 for recurrence, 2p<0 . 00001 for breast cancer mortality) more effective than CMF chemotherapy. Few women of age 70 years or older entered these chemotherapy trials. For ER-positive disease only, allocation to about 5 years of adjuvant tamoxifen reduces the annual breast cancer death rate by 31% (SE 3), largely irrespective of the use of chemotherapy and of age (<50, 50-69, &GE; 70 years), progesterone receptor status, or other tumour characteristics. 5 years is significantly (2p<0 . 00001 for recurrence, 2p=0 . 01 for breast cancer mortality) more effective than just 1-2 years of tamoxifen. For ER-positive tumours, the annual breast cancer mortality rates are similar during years 0-4 and 5-14, as are the proportional reductions in them by 5 years of tamoxifen, so the cumulative reduction in mortality is more than twice as big at 15 years as at 5 years after diagnosis. These results combine six meta-analyses: anthracycline-based versus no chemotherapy (8000 women); CMF-based versus no chemotherapy (14 000); anthracycline-based versus CMF-based chemotherapy (14 000); about 5 years of tamoxifen versus none (15 000); about 1-2 years of tamoxifen versus none (33 000); and about 5 years versus 1-2 years of tamoxifen (18 000). Finally, allocation to ovarian ablation or suppression (8000 women) also significantly reduces breast cancer mortality, but appears to do so only in the absence of other systemic treatments. For middle-aged women with ER-positive disease (the commonest type of breast cancer), the breast cancer mortality rate throughout the next 15 years would be approximately halved by 6 months of anthracycline-based chemotherapy (with a combination such as FAC or FEC) followed by 5 years of adjuvant tamoxifen. For, if mortality reductions of 38% (age <50 years) and 20% (age 50-69 years) from such chemotherapy were followed by a further reduction of 31% from tamoxifen in the risks that remain, the final mortality reductions would be 57% and 45%, respectively (and, the trial results could well have been somewhat stronger if there had been full compliance with the allocated treatments). Overall survival would be comparably improved, since these treatments have relatively small effects on mortality from the aggregate of all other causes. Interpretation Some of the widely practicable adjuvant drug treatments that were being tested in the 1980s, which substantially reduced 5-year recurrence rates (but had somewhat less effect on 5-year mortality rates), also substantially reduce 15-year mortality rates. Further improvements in long-term survival could well be available from newer drugs, or better use of older drugs.
  •  
6.
  •  
7.
  •  
8.
  •  
9.
  • Lawler, M., et al. (författare)
  • The European Cancer Patient's Bill of Rights, update and implementation 2016
  • 2016
  • Ingår i: Esmo Open. - 2059-7029. ; 1:6
  • Tidskriftsartikel (refereegranskat)abstract
    • In this implementation phase of the European Cancer Patient's Bill of Rights (BoR), we confirm the following three patient-centred principles that underpin this initiative: 1. The right of every European citizen to receive the most accurate information and to be proactively involved in his/her care. 2. The right of every European citizen to optimal and timely access to a diagnosis and to appropriate specialised care, underpinned by research and innovation. 3. The right of every European citizen to receive care in health systems that ensure the best possible cancer prevention, the earliest possible diagnosis of their cancer, improved outcomes, patient rehabilitation, best quality of life and affordable health care. Agree our high-level goal. The vision of 70% longterm survival for patients with cancer in 2035, promoting cancer prevention and cancer control and the associated progress in ensuring good patient experience and quality of life. Establish the major mechanisms to underpin its delivery. (1) The systematic and rigorous sharing of best practice between and across European cancer healthcare systems and (2) the active promotion of Research and Innovation focused on improving outcomes; (3) Improving access to new and established cancer care by sharing best practice in the development, approval, procurement and reimbursement of cancer diagnostic tests and treatments. Work with other organisations to bring into being a Europe based centre that will (1) systematically identify, evaluate and validate and disseminate best practice in cancer management for the different countries and regions and (2) promote Research and Innovation and its translation to maximise its impact to improve outcomes.
  •  
10.
  •  
Skapa referenser, mejla, bekava och länka
Typ av publikation
tidskriftsartikel (650)
konferensbidrag (173)
forskningsöversikt (12)
bokkapitel (3)
annan publikation (2)
rapport (1)
visa fler...
visa färre...
Typ av innehåll
refereegranskat (611)
övrigt vetenskapligt (229)
populärvet., debatt m.m. (1)
Författare/redaktör
Bergh, J (647)
Foukakis, T (83)
Bergh, Jonas (81)
Hatschek, T (59)
Lindman, H (50)
Hartman, J (48)
visa fler...
Bergh, C. (39)
Tobin, NP (38)
Hall, P (34)
Cardoso, F (34)
Blomqvist, C (32)
Holmberg, L (32)
Matikas, A (32)
Malmstrom, P (31)
Cameron, D. (30)
Wilking, N (30)
Lindstrom, LS (30)
Bergh, A (29)
Bergh, Christina, 19 ... (29)
Bengtsson, NO (28)
Ahlgren, J (28)
Lidbrink, E (27)
Johansson, H (26)
Lovrot, J (26)
Bjohle, J (26)
Czene, K (25)
Piccart, M (25)
Klaar, S (25)
Bergh, Anders (24)
Nygren, P (24)
Smeds, J (24)
Bonnefoi, H (24)
Gnant, M. (23)
Linderholm, B (23)
Brandberg, Y (23)
Carlsson, L. (23)
Hellstrom, M (23)
Fornander, T (23)
Einbeigi, Z (23)
Ostman, A (22)
Nordgren, H (22)
Fredriksson, I (21)
Skoog, L (20)
Zerdes, I (20)
Warnberg, F (19)
Harbeck, N (19)
Karlsson, E (19)
Loman, N (19)
Jassem, J. (19)
Delorenzi, M (19)
visa färre...
Lärosäte
Karolinska Institutet (567)
Uppsala universitet (166)
Göteborgs universitet (80)
Lunds universitet (57)
Umeå universitet (50)
Linköpings universitet (31)
visa fler...
Örebro universitet (19)
Chalmers tekniska högskola (15)
Kungliga Tekniska Högskolan (13)
Stockholms universitet (9)
Linnéuniversitetet (7)
Karlstads universitet (7)
Ersta Sköndal Bräcke högskola (4)
Jönköping University (2)
Högskolan i Skövde (2)
Gymnastik- och idrottshögskolan (2)
Högskolan i Gävle (2)
Sveriges Lantbruksuniversitet (2)
Mälardalens högskola (1)
Malmö universitet (1)
Mittuniversitetet (1)
Södertörns högskola (1)
RISE (1)
Försvarshögskolan (1)
Sophiahemmet Högskola (1)
visa färre...
Språk
Engelska (837)
Svenska (4)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (185)
Naturvetenskap (45)
Lantbruksvetenskap (11)
Samhällsvetenskap (9)
Teknik (3)
Humaniora (1)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy